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Background: Hyperhomocysteinemia (HHcy) is prevalent in hypertensive patients and is 
an independent risk factor for aortic pathologies. HHcy is known to cause an imbalance 
between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases 
(TIMPs) leading to accumulation of collagen in the aorta resulting in stiffness and 
development of hypertension. Although the exact mechanism of extracellular matrix 
remodeling (ECM) is unclear, emerging evidence implicates epigenetic regulation 
involving DNA methylation. The purpose of the study was to investigate whether 
inhibition of DNA methylation reduces high blood pressure by regulating aortic ECM 
remodeling in HHcy. 
Methods: In the first set of experiments, we studied the effect of HHcy in causing 
epigenetic changes leading to aortic remodeling resulting in hypertension. Cystathionine 
beta synthase heterozygous knockout (CBS+/-) mice of C57BL/6J background were used 
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as HHcy model and their Wild type (WT) littermates were used as controls. Hcy level in 
plasma was measured by HPLC-UV. Blood pressure was measured using tail-cuff 
method. The mRNA expression levels of ECM proteins and epigenetic modifications 
enzymes in the aorta were measured by RT-PCR. Global methylation level was measured 
by ELISA. 
In the second set of experiments, we studied effects of an epigenetic DNA 
methyltransferase inhibitor, 5-Aza-2’-deoxycytidine (Aza) in HHcy. For in vivo studies, 
we used 8-12 weeks old WT and CBS+/- mice and administered them with Aza for four 
weeks. During the treatment period, blood pressure was measured using tail-cuff method. 
Aorta wall thickness, lumen diameter and resistive index were measured before and after 
treatment using ultrasound. Aortic responses to vasoconstrictor and vasodilators were 
measured using tissue myobath. Collagen accumulation in the aortic walls was measured 
by Mason Trichrome and Picrosirius red staining. ECM proteases, Hcy metabolism 
enzymes and DNMT1 expression were measured using immunostaining. Global 
methylation levels were assessed using ELISA. For cell culture studies, mouse aortic 
smooth muscle cells were treated with Aza and Hcy for 48 hrs. MMP9 activity was 
measured using gelatin zymography and DNMT1, 3a and 3b expression was measured 
using immunoblotting. 
Results: In CBS+/- mice, increased plasma Hcy levels were associated with an increase 
in blood pressure. There was an increase in the mRNA levels of collagen and decrease in 
elastin in HHcy mice. Global hypermethylation was accompanied by an increased 
expression of methylation proteins in HHcy.  Aza treatment normalized plasma SAM, 
SAH and Hcy levels and blood pressure in HHcy mice. Thoracic and abdominal aorta 
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ultrasound revealed reduction in resistive index and wall-to-lumen ratio. Vascular 
response to vasoactive agents improved following Aza treatment in HHcy. Histology 
showed a marked reduction in collagen deposition in the aorta. Aza treatment decreased 
the expression of DNMT1, 3b, MMP9, TIMP1 and S-adenosyl homocysteine hydrolase 
(SAHH) and upregulated methylene tetrahydrofolate reductase (MTHFR) 
Conclusion: We conclude that reduction of DNA methylation in HHcy reduces adverse 
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Cardiovascular diseases cause to about 13.4 million deaths annually worldwide 
and are a major global economic concern [1, 2]. Although arterial diseases are not the 
most common of the cardiovascular diseases (CVD), they cause 3.4% of deaths due to 
CVD (Figure 1) [3]. Data from the Centers for Disease Control and Prevention (CDC) 
state that diseases of the aorta and its branches account for 43,000 to 47,000 deaths 
annually in the United States [4]. Many risk factors including age, lifestyle, hypertension 
and elevated plasma homocysteine (Hcy) levels contribute to the occurrence of aortic 
diseases. 
Homocysteine (Hcy) is a non-protein forming, non-essential amino acid that is an 
intermediate in methionine metabolism. Plasma Hcy levels varies between individuals 
and elevated plasma Hcy (hyperhomocysteinemia, HHcy), is associated with increased 
risk of CVD. In 2004, Giusti et al., report an increase in total plasma Hcy levels in 
patients with aortic dissection and abdominal aortic aneurysm [5]. The biological effects 
of HHcy relevant to aortic diseases include increased oxidative stress, pro – inflammatory 




Extracellular matrix (ECM) provides physical support and triggers various 
signaling pathways within all tissues and organs. The production of ECM proteins such 
as collagen, or proteases such as matrix metalloproteinases (MMPs) and their inhibitors, 
tissue inhibitors of metalloproteinases (TIMPs) play a crucial role in determining the 
structure and function of the aorta. In aortic diseases, the balance between expressions of 
different ECM components is disrupted, leading to remodeling.  
Emerging evidence suggests that epigenetic modifications play an important role 
in controlling a wide spectrum of biological processes. DNA methylation regulates gene 
expression during fetal reprogramming and contributes to the development of an 
extensive range of chronic pathologies. DNA methylation is facilitated by the enzyme, 
DNA methyltransferase (DNMT) that catalyze the transfer of a methyl group to 
previously unmethylated DNA. Several studies suggest that changes in epigenetic 
modifications can be caused by age, environmental factors/lifestyle, or various diseases 
[10-13]. Hence, the US Food and Drug Administration has approved drugs that 
specifically target epigenetic modifications such as DNA methylation and histone 
modification molecules which are currently in therapeutic use for diseases such as stroke 
and cancer [14, 15]. Nevertheless, it is unknown whether epigenetic inhibitors have a 
therapeutic role in HHcy-induced hypertension. In the current study, we examined the 
epigenetic modifications involved in aortic ECM remodeling in HHcy induced 











Figure 1: Percentage breakdown of deaths attributable to cardiovascular diseases 
(United States: 2010). Source: National Heart, Lung, and Blood Institute from National 

















The aorta, which is the largest artery in the body, supplies oxygenated blood from 
the left ventricle to systemic circulation. The aorta can be divided into different sections 
based on areas that its branching arteries supply: the ascending aorta supplies blood to the 
heart, the arch of the aorta supplies the head, neck and arms, and the descending aorta 
supplies the lower half of the body (Table 1). A study of the thoracic aortic diameters 
using computed tomography reveals that the diameter of the ascending aorta is larger 
than the diameter of  the descending thoracic aorta and the aorta in a normal healthy adult 
dilates with age at a rate of 0.1cm per decade [16]. The aorta is composed of three tunics 
or layers: the intima, media and adventitia. The innermost layer or intima consists of a 
layer of squamous endothelial cells, an acid mucopolysaccharide rich extracellular matrix 
composed of fibroblasts and macrophages, and elastic lamella. The media comprises of 
elastic fiber rings separated by layers of collagen and elastin fibers with undifferentiated 
smooth muscle cells. The concentric elastic lamellae contribute to the radial strength and 
elasticity of the aorta.  The outermost layer or adventitia, consists of a thin collagen rich 
layer of fibroblasts, smooth muscle cells and vasa vasorum. Vasa vasorum are a network 
of arterioles that provide a vascular supply to the aorta [17]. Aortic diseases can be 
classified as aortic valve diseases such as those that affect the bicuspid aortic valve, or 
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aortic disorders due to changes in its wall composition such as atherosclerosis, aortic 
aneurysm and aortic dissection. 
 
Aorta Branches  
Ascending aorta Coronary arteries 
 
Arch of the aorta 
 
Innominate 
Left common carotid 










Visceral – Pericardial, Bronchial, Esophageal, 
Mediastinal 
Parietal – Intercostal, Subcostal, Superior phrenic 
 
Visceral – Celiac, Superior mesenteric, Inferior 
mesenteric, Middle suprarenals, Renals, Internal 
spermatics, Ovarian (in females) 
Parietal – Inferior phrenics, Lumbars, Middle sacral 
Terminal – Common iliacs 
 
Table 1: The aorta and its branches  
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Bicuspid aortic valves 
Bicuspid aortic valves are characterized as two unequally sized leaflets instead of 
the normal tricuspid aortic valve [18].  This congenital abnormality is most commonly 
identified as a systolic ejection click during exam.  It is present in about 1-2% of the 
population and the anomaly often has no symptoms, although the coronary arteries may 
be abnormal and sometimes the aortic root is dilated. A causal relationship between aortic 
aneurysm and bicuspid aortic valves has been hypothesized [19]. 
Atherosclerosis 
Atherosclerosis can affect any artery of the body. Aortic plaques are a common 
feature of atherosclerosis which is found in elderly people. Plaques are formed due to 
deposition of fat, cholesterol and calcium in the intimal layers of arteries. These plaques 
harden and narrow the vessel diameter causing obstruction to blood flow. Plaques with 
thickness ≥ 4 mm are termed severe plaques and are susceptible to embolization. The 
plaque can disintegrate, forming a blot clot and can result in pathophysiological 
complications such as heart attack, stroke and peripheral artery diseases. Some risk 
factors associated with atherosclerosis are hypertension, hypercholesterolemia, age, 
smoking, diabetes, increased levels of homocysteine, thrombotic diathesis markers such 
as prothrombin and activated protein C resistance, and inflammatory markers like white 






An aneurysm is an abnormal, irreversible dilation caused by weakness due to a 
decrease in elastin in the arterial wall.  Abdominal aortic aneurysms (AAA) are known to 
be associated with atherosclerosis, hypertension, hyperhomocysteinemia and smoking 
[25-28]. The most common site for an aneurysm to develop is in the abdominal aorta.  
Most AAA occurs below the level of the renal arteries.  They may affect the bifurcation 
of the aorta as well as the iliac arteries.  Aneurysms often increase in size; they can 
rupture and lead to hemorrhage and even death.  If an aneurysm is greater than 5 cm, 
surgery is generally recommended. In the descending thoracic and abdominal aorta, 
aneurysms result from severe intimal atherosclerosis, increased elastin and collagen 
degrading enzymes and pro-inflammatory cytokines, chronic inflammation, and 
remodeling of the elastic media [5]. Important risk factors of aortic aneurysm include 
cigarette smoking, age, gender, hypertension and elevated levels of homocysteine [29]. 
Thoracic aortic aneurysms (TAA), like AAA, are caused due to atherosclerosis, 
trauma, and hypertension. Other unique factors which have been found to play a major 
role in causing TAA are syphilis [30], Marfan syndrome (MFS), and bicuspid aortic 
valves. Aneurysms in the ascending aorta are due to degeneration of the aortic media by 
cystic medial necrosis (CMN): loss of smooth muscle cells and degeneration of elastic 
fibers. Accelerated CMN has been known to be associated with genetic syndromes, like 
MFS [5] 
MFS is an autosomal dominant condition affecting connective tissue that is 
characterized by skeletal, ocular, and cardiovascular problems.  MFS patients have 
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thoracic aortic aneurysms and dissections (TAA/TAD) as well as valvular abnormalities, 
like bicuspid aortic valve [31].  CMN in MFS patients may be caused by abnormal 
fibrillin-1 which is a part of the elastic fiber that surrounds an elastin core.  This results in 
a weakened aortic wall due to loss of intact elastin. 
Aortic Dissection 
Dissection is a condition which is distinct from aneurysm and may affect the 
thoracic or abdominal aorta. An intimal tear leads to separation of layers of the aortic 
wall and forms a passageway for blood flow. This diverts blood flow throughout the aorta 







Homocysteine (Hcy) is a non-protein coding amino acid derived from dietary 
methionine. In the plasma, 70% of Hcy is bound to albumin, 1% exists as free thiols and 
the remainder is bound to cysteine by disulfide linkages, or as Hcy dimers. Dietary 
methionine gets activated by adenosine triphosphate (ATP) and three isoenzymes of 
methionine adenosyl triphosphate (MAT I, II and III) to form S-adenosyl methionine 
(SAM), a universal methyl donor. The methyl group of SAM is activated by the positive 
charge of its sulfur atom and gets removed from SAM to form S-adenosyl homocysteine 
(SAH). This highly reactive methyl group methylates various substrates such as proteins, 
RNA, phospholipids, myelin, catecholamines, polysaccharides, creatine, carnitine and 
DNA. SAH is hydrolyzed by SAH hydrolase (SAHH), in a reversible reaction, to yield 
Hcy. Total plasma Hcy levels are sometimes denoted as tHcy. Normal plasma Hcy levels 
in humans are between 5 and 15µM [33].  
Hcy gets metabolized through two pathways – trans-sulfuration and remethylation 
(Figure 2). In most tissues, Hcy is remethylated to methionine by vitamin B12 dependent 
methionine synthase (MS). MS uses a methyl group from the de-methylation of methyl 
tetrahydrofolate (methyl THF). Methyl THF is one of the intermediates in the folate 
metabolism pathway, which is synthesized from 5, 10 methylene-tetrahydrofolate 
catalyzed by methylene tetrahydrofolate reductase (MTHFR). In liver and kidneys, Hcy 
remethylation is carried out by betaine Hcy methyltransferase (BHMT). The 
transsulfuration pathway is active in liver, kidney, small intestine and pancreas. Hcy 
condenses with serine and gets converted to cystathionine in the presence of vitamin B6 
activated enzyme, cystathionine beta synthase (CBS). Cystathionine is hydrolyzed by  
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cystathionase to cysteine and α ketobutyrate. CBS removes Hcy from the methionine 
cycle permanently by catalyzing the synthesis of cystathionine from Hcy and serine [34].    
Hyperhomocysteinemia (HHcy) 
Plasma levels greater than 15 µM are termed hyperhomocysteinemia (HHcy). 
Based on plasma Hcy levels, HHcy can be categorized as mild (16-30 µM), moderate 
(31-100 µM) and severe (>100 µM) [33]. Literature, however, suggests that plasma Hcy 
levels above 10 µM, increases the risk for incidence of cardiovascular diseases [35]. A 
clinical study done in 2004 reported an increase in the plasma Hcy levels of patients with 
abdominal aortic aneurysm (15.7 ± 6.5 µM) [28] (Figure 3) and aortic dissection (Figure 
3) [5, 36].  In patients with AAA, there was an increased trend in the expression of 
SAHH, MTHFR and the expression of CBS when compared to healthy subjects [37]. A 
similar trend was observed in patients with TAA. These results suggest a compensatory 
increase in the Hcy metabolism proteins, MTHFR and CBS to combat HHcy during 
aortic aneurysm (Figure 4) [37]. 
Genetic mutations and polymorphisms 
Although several causative factors are responsible for HHcy, genetic mutation is 
one of the most important influences (Figure 5). Mutations in the genes involved in the 
Hcy metabolism pathway, inhibits their expression, resulting in changes in Hcy levels in 
the body. Since folate is a cofactor in remethylation of Hcy, without MTHFR, plasma 
Hcy levels increase. MTHFR polymorphisms impair the ability to process folate, 
resulting in a defective Hcy remethylation pathway. The most common MTHFR 
polymorphism is C677T (thermolabile mutation). In this mutation, the C->T conversion 
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in the gene code at nt 677 results in an alanine to valine substitution. This change in the 
amino acid sequence decreases the activity of MTHFR at higher temperature 
(thermolability). Wong et al., report that in AAA, plasma Hcy levels were greater in 
MTHFR TT homozygote individuals than in wild type CC controls [38]. Another 
MTHFR polymorphism is A1298C, where the A->C conversion in the genetic code at nt 
1298 leads to aglutamate to alanine substitution. This polymorphism also results in 
decreased MTHFR activity; however, its impact on tHcy is lesser than that of the C677T 
mutation. Individuals heterozygous for both of these mutations exhibit decreased 
MTHFR activity and plasma folate levels and increased tHcy [39]. In 1966, Mudd et al., 
report that people with HHcy due to a severe genetic defect of CBS, are affected with 
premature arteriosclerosis and frequent thromboembolisms [40]. Since mutations in the 
Hcy metabolism genes lead to accumulation of Hcy, knockout mice models for MTHFR 
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Figure 3: Total plasma Hcy (tHcy) levels are increased in patients with abdominal 
aortic aneurysm (AAA) and aortic dissection. The above data are reproduced from a 
2004 article by Dr. Giusti et al., [5]. The above data show an increase in tHcy levels in 
aortic aneurysm and aortic dissection. (B – Patients with mild cardiovascular system 







Figure 4: CBS expression was increased in aortic aneurysm [37]. RNA extracted from 
various human aortic tissue samples were reverse transcribed and amplified using primers 
designed for CBS, MTHFR, SAHH.  Data are shown as mean ± SEM. * p<0.05 vs. 
normal controls, † p<0.05 vs. AAA (n=4). Ctrl – controls, AAA – abdominal aortic 
aneurysm, TAA – thoracic aortic aneurysm, CBS – Cystathionine beta synthase, MTHFR 








































Hyperhomocysteinemia and vascular dysfunction 
In 1969, Kilmer McCully report subjects with homocystinuria, an inherited 
disorder of HHcy and increased Hcy concentration in urine associated with CBS 
deficiency, exhibit vascular complications including increased smooth muscle 
proliferation, progressive stenosis and hemostatic changes [42, 43]. Several mechanisms 
are proposed by which HHcy may lead to vascular damage. Hcy can induce oxidative 
stress due to increased production of reactive oxygen species (ROS) [44, 45]. ROS 
decreases the bioavailability of nitric oxide, a primary mediator of vasorelaxation, 
reacting with nitric oxide and forming peroxynitrate. Hcy impairs endothelium-dependent 
vasodilation due to reduced bioavailability of nitric oxide [44, 46], increased levels of 
asymmetric dimethylarginine (an intermediate formed during proteolysis of methylated 
proteins) [47] and endothelial dysfunction [48].  Hcy triggers the expression and release 
of cytokines such as monocyte chemotactic protein 1 (MCP1) and IL-8, specific for 
neutrophils and monocytes which cause inflammation [49-52]. Hcy can also induce 
mobilization of intracellular calcium, causing platelet aggregation in type 2 diabetes 
mellitus [53]. Other mechanisms suggest that Hcy enhances LDL oxidation and lipid 
peroxidation [54-56], increases smooth muscle proliferation [57], causes abnormal 
platelet function [58-60] and causes extracellular matrix remodeling in arteries [61] and 
veins [62].    
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Extracellular matrix remodeling 
The structural design of different components of the extracellular matrix (ECM) is 
necessary for understanding the mechanical properties of tissues. ECM is the non-cellular 
component which provides physical scaffolding for the cellular constituents and initiates 
crucial biochemical and biomechanical signaling mechanisms. ECM consists of different 
types of components – Fibrous proteins like collagen and elastin; matrix 
metalloproteinases and tissue inhibitor of matrix metalloproteinases.  
Fibrous proteins - Collagen and Elastin 
The fibrous proteins provide the structural support for vessels. Both collagen and 
elastin make up the wall of the aorta.  Collagen provides rigidity and is responsible for 
the mechanical strength of the vessels. There are about 16 different types of collagen 
known in the body. Col I is about 90% of all human collagen and is present in most 
tissues. Col I, III, IV and V are abundantly found in arterial wall. Both Col I and III are 
the major constituents of the intima, media and adventitia. There was a decrease in the 
expression of Col I in AAA (Figure 6) [37].  Col IV and V are localized to the endothelial 
basement membrane and basement membranes of smooth muscle cells of the intima and 
media. In TAA, decreased expression of Col I and IV have been reported (Figure 6) [37] . 
Diffusely distributed type V collagen was also observed in the intercellular space of the 
intima [63].  
Elastin is responsible for the reversible extensibility during cyclic loading of the 
cardiac volume. Elastic fibers are organized in the medial layer of the aorta as an 
interconnecting, fenestrated network. Each layer of elastic fibers is associated with 
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circumferentially oriented smooth muscle cells and collagen fibers and constitutes a 
lamellar unit. The number of units is established during development and is directly 
related to the tension in the arterial wall, so that the tension/lamellar unit is constant 
across the body and the arterial tree [64]. Elastin undergoes degradation and alterations 
with increasing age and various pathologies resulting in arterial wall stiffness [65]. 
Increased arterial stiffness is an important, independent predictor of cardiovascular 
mortality in hypertension, end-stage renal failure, diabetes, and elderly adults [66]. 
Arterial stiffness triggers a negative feedback cycle that increases the mechanical load on 
the heart and leads to heart failure [67].  
Patients with homozygous CBS deficiency showed an increased internal and 
external diameter of the common carotid arteries [68]. Arterial histological analysis of 
homocystinuric patients showed medial changes and internal elastic laminal 





Figure 6: Collagen I was decreased in AAA and TAA tissues. RNA extracted from 
various human aortic tissue samples were reverse transcribed and amplified using primers 
designed for Collagen I, Collagen IV, Elastin. Data are shown as mean ± SEM. *p<0.05 
vs. healthy controls (n=4), ‡ p<0.05 vs. healthy controls and TAA samples (n=4); AAA – 
abdominal aortic aneurysm, TAA – thoracic aortic aneurysm, Ctrl – controls, Col1 – 





Matrix metalloproteinases (MMPs)  
Regulated ECM synthesis and degradation is necessary for development, 
morphogenesis, wound healing, and tissue repair and remodeling. Matrix 
metalloproteinases (MMPs), also known as matrixins, are responsible for the timely 
degradation of ECM under normal physiological conditions. MMPs play a major role in 
tadpole tail metamorphosis by Gross and Lapiere in 1962 [71]. MMPs are zinc and 
calcium dependent endopeptidases which are primarily secreted in cells such as 
fibroblasts, vascular smooth muscle, macrophages, neutrophils and mast cells. Based on 
the molecular structure, substrate specificity and mechanism of activation, MMPs are 
classified into four groups: archetypal MMPs, matrilysins, gelatinases and furin-activated 
MMPs [72].  
Archetypal MMPs are further divided into three subgroups: collagenases, 
stromelysins and other archetypal MMPs. Collagenases are classified as: collagenase-1 
(MMP-1), collagenase-2 (MMP-8), and collagenase-3 (MMP-13). Collagenases cleave 
native collagens into characteristic N-terminal ¾ and C-terminal ¼ fragments. MMP-1 
initiates cleavage of fibrillar collagens at a single site so that other MMPs can further 
degrade collagen [73]. The main sources of collagenases are activated fibroblasts (MMP-
1), neutrophils (MMP-8) and vascular smooth muscle cells (MMP-1 and MMP-13). 
Collagenases are abundantly present in aortic aneurysm tissues [74]. Stromelysins are 
classified as stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10). Stromelysins are 
structurally similar to collagenases, but they do not possess the ability to cleave native 
collagens. MMP-3 is more proteolytic than MMP-10 and activates various pro-MMPs 
[75, 76]. Although stromelysin is primarily produced by vascular smooth muscle cells 
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and fibrobalsts, in aortic aneurysm they are derived from macrophages.  Other archetypal 
MMPs include MMP-12, MMP-19, MMP-20 and MMP-27. MMP-12, macrophage 
metalloelastase, is primarily expressed and secreted by activated macrophages and 
mainly cleaves elastin.  
Matrilysins lack a hemopexin domain and are represented by matrilysin-1 (MMP-
7) and matrilysin-2 (MMP-26, or endometase). Matrilysins play an important role in 
degradation of ECM molecules, including Col IV, laminin and may be responsible for 
apoptosis and inhibition of angiogenesis. MMP-26 is the smallest known MMP and is 
involved in the activation of MMP-9 [77]. 
Gelatinases consists of gelatinase A (MMP-2) and gelatinase B (MMP-9). Both 
are constitutively expressed by cells, including fibroblasts, keratinocytes, endothelial 
cells, polymorphonuclear leukocytes, monocytes, alveolar macrophages and osteoclasts. 
When compared to other MMPs, gelatinases possess three type II fibronectin-like repeats 
within their catalytic domain. Gelatinases may cleave various ECM substrates such as 
gelatin, collagen types I, IV, V, VII, IX, X, elastin, fibronectin, aggrecan, vitronectin, 
laminin, as well as non-ECM molecules, including pro-TNF, TGF-β, pro-IL-1β and pro-
IL-8 [78]. MMP-9 is the most abundant elastase in human AAA tissue.  It is also 
expressed by aneurysm-infiltrating macrophages at the site of damaged tissue. MMP-9 is 
correlated with higher aneurysm diameters (Figure 7) and is present in high amounts in 
the plasma of patients with AAAs [79].   
Furin-activated MMPs have a unique sequence inserted between the prodomain 
and the catalytic domain which is cleaved by furins (pro-protein convertases or serine 
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proteinases), thereby activating the enzymes. These MMPs are divided into two 
subgroups: secreted MMPs, (membrane-type I and type II MMPs) and GPI-anchored 
MMPs. The furin-activated secreted MMPs include MMP-11, MMP-21 and MMP-28. 
Type I transmembrane MMPs include: MT1-, MT2-, MT3-, and MT5-MMP (MMP-14, -
15, -16, and -24, respectively. Type II transmembrane MMPs consist of MMP-23A and 
MMP-23B and GPI-anchored MMPs include MT4-MMP and MT6-MMP (MMP-17 and 
-25, respectively). MT-MMP-1 plays an important role in the pathogenesis of aortic 
aneurysm. Besides degradation of ECM components, MT1-MMP activates MMP-2 and 
facilitates migration of macrophages, thus promoting inflammatory infiltration of the 





Tissue inhibitors of MMPs 
Tissue inhibitors of matrix metalloproteinases (TIMPs) prevent aortic wall 
destruction and prevent aneurysm development by inhibiting MMPs  [80].  TIMPs are 
secreted by cells, including macrophages, VSMC and platelets. TIMPs bind to the 
catalytic domain of MMPs and block their enzymatic activity. TIMPs possess differential 
affinity to MMPs, for example, TIMP-1 preferably binds to MT-MMPs. The presence of 
MMP-neutralizing agents such as α2-macroglobulin prohibits a direct interaction between 
TIMPs and active MMPs [81]. TIMP-1 is a collagenase inhibitor while TIMP-4 is 
secreted extracellularly primarily from heart tissue and may be involved with 
extracellular matrix homeostasis [82]. TIMP-2 plays a major role in the activation of 
MMP2. TIMP-2 binds to the hemopexin domain of pro-MMP-2 which is necessary for 
MT1-MMP to activate MMP-2 [83]. 
Functional polymorphisms in genes encoding for TIMPs could influence the 
activity of MMPs in the aneurysm wall. Several single nucleotide polymorphisms (SNPs) 
which could affect TIMP transcription were assessed in patients with aortic aneurysms. 
The genotyping results were analyzed for male and female patients separately since the 
TIMP-1 gene is located on the X chromosome. The literature suggests that two 
polymorphisms for TIMP-1 (434 C/T and rs2070584 T/C) [84] and two for TIMP-2 (a 
promoter SNP -479 C/T, and 573 G/A, but in male patients group only) [85, 86] are 
associated with aortic aneurysm. Although TIMP-1 mRNA expression levels did not 
change significantly, TIMP-4 mRNA levels were higher in abdominal aortic aneurysm 




Figure 7: TIMP4 expression was increased in AAA [37]. RNA extracted from various 
human aortic tissue samples were reverse transcribed and amplified using primers 
designed for MMP1, TIMP1, MMP9, TIMP4. Data are shown as mean ± SEM. *p<0.05 
vs. normal (n=4) ; AAA – abdominal aortic aneurysm, TAA – thoracic aortic aneurysm, 








In a eukaryotic nucleus, the basic unit of chromatin consists of 147 base pairs of 
DNA wrapped around two copies of four histone proteins H2A, H2B, H3 and H4 [87]. 
Histone proteins consist of a globular carbosyl-terminal domain and an amino-terminal 
tail which project from the nucleosome core. The amino tails of the histone proteins are 
susceptible to post translational modifications such as acetylation, methylation, 
phosphorylation, ubiquitination, sumolysation and ADP-ribosylation [88]. These 
inheritable histone modifications affect gene transcription, and maintenance of epigenetic 
information by making a histone modification signature or a “histone code” [89].  
Epigenetics can be described as the inheritable changes occurring beyond the 
genetic makeup, without affecting the actual nucleotide sequence. Every organism carries 
a certain epigenetic pattern throughout its pedigree. These epigenetic patterns are 
translated to phenotypic expression due to the regulation of gene transcription exerted by 
the epigenetic modifications.  However, this epigenetic blueprint can be altered by 
various environmental factors like diet, hormonal imbalance during physical stress and 
pollutants [90-92]. The most commonly studied epigenetic modifications are – DNA 
methylation and histone modifications (Figure 8). Normally, histone modifications have 
short-term gene expression effects and DNA methylation is considered to be long-term 






DNA methylation is an epigenetic modification involving an addition of methyl 
group to the cytosine residues at the 5-carbon position. Methylated cytosine (5-mC), was 
first described in 1925 by Johnson and Coghill [93]. In mammals, 5-mC is primarily 
found in cytosine-guanidine rich regions in the gene called CpG islands. They account for 
approximately 7% of CpG dinucleotides genome-wide and are associated with the 5′-
regulatory regions of ≈40% to 60% of human genes [94, 95]. These islands are found 
mostly at the upstream promoter regions of the genes. Since promoter region 
modifications are essential in regulating the binding of transcription factors, CpG island 
methylation plays a major role in controlling gene expression. In healthy somatic cells, 
70% to 90% of CpG dinucleotides, representing 3% to 6% of all cytosines, are 
methylated [95]. DNA methylation is facilitated with the help of DNA methyltransferases 
(DNMTs). There are mainly three active DNMTs : DNMT1, DNMT3a and DNMT3b. 
DNMT3a and 3b facilitate de novo methylation which is responsible for methylation 
patterns during early embryo development [96]. DNMT1 is primarily found in somatic 
cells and is localized to the DNA replication fork, where it is specific to hemi-methylated 
DNA. It is involved in maintenance methylation.   
DNA methylation is associated with transcriptional silencing in a growing number 
of cellular functions, such as X chromosome inactivation, genomic imprinting, 
mammalian embryonic development, and lineage specification [94, 95]. Aberrant DNA 
methylation patterns have been associated with various diseases. For example, the cancer 
genome is characterized by genome-wide hypomethylation and paradoxical 
hypermethylation of CpG islands associated with tumor-suppressor genes. 
27 
 
DNA methylation can affect gene expression in two different ways. First, since 
methyl groups of CpG dinucleotides project into the major groove of the DNA helix, it 
prevents the binding of transcription factors such as Myc, activator protein-2, -19, 
hypoxia-inducible factor -1α, -20 and the insulator protein CTCF21, -22 to CpG 
dinucleotide-containing cis-DNA binding elements. However it is likely that this 
mechanism is not relevant for a majority of transcription factors whose target genes are 
regulated by DNA methylation [95]. Second, a group of methyl-CpG binding proteins are 
capable of specifically recognizing the mammalian methylated CpG rich regions which 
act as transcriptional repressors.  These include proteins containing a homologous 
methyl-CpG-binding domain (MBD1, MBD2, MBD4, and MeCP2) and nonhomologous 
protein, Kaiso, which is capable of binding methylated CpG dinucleotide doublet [97]. 
These proteins can directly repress transcription, prevent the binding of activating 





Although the nucleosome is a tight structure, histone post-translational modifications can 
affect the chromatin structure and function and hence modulate the accessibility of 
transcriptional regulators to cis-DNA binding elements. Histone modifications at a 
certain promoter region determine the epigenetic state of the genome, and one of the most 
important types of histone modifications is acetylation [98]. Histone acetylation 
neutralizes the positive charge of the lysine residues, thereby disrupting the electrostatic 
attraction between histone proteins and negatively charged DNA. This interaction results 
in a change from heterochromatin to euchromatin, allowing the transcription initiation 
complex to access DNA promoter. Thus, euchromatin is the transcriptionally active 
region and is associated with acetylated histones and hypo-methylated DNA. 
Heterochromatin, however, is transcriptionally repressed and bound to non-acetylated 
histones and hyper-methylated.  
Histone acetylation is regulated by the balanced activities of two key enzymes - histone 
acetyl transferase (HATs) and histone de-acetylase (HDACs) [99]. HATs acetylate lysine 
residues and result in an open chromatin promoting gene transcription, whereas HDACs 
remove acetyl groups and condense the chromatin causing transcriptional repression 
[100]. Some proteins function as transcriptional activators such as p300 which possess 
intrinsic HAT activity [99]. A previous report suggests that HAT and HDACs play a 
major role in the development of atherosclerosis and restenosis due to their regulatory 
role in processes such as inflammation, proliferation of VSMCs and matrix remodeling 
[101]. HDACs aid in maintaining endothelial function and structural integrity of the 
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vessels by regulating the expression of proteins involved in angiogenesis such as vascular 
endothelial growth factor [102, 103]  
Histones methylation takes place on either lysine (K) or arginine (R) residues providing 
binding sites for recruitment of other regulatory proteins [104]. Methylated histones such 
as H3K9, H3K27, H3K79 and H4K20 are associated with gene repression, whereas 
activated genes are associated with methylated H3K4 and H3K36 residues [104]. Histone 
methylation is carried out by histone methyl transferase (HMT), whereas histone 
demethylases (HDMs) remove methylation. Proteins involved in DNA methylation 
mechanism such as DNA methyl transferase and methyl-binding proteins interact with 
histone-methylating enzymes, resulting in cross talk between the histone and DNA 
methylation pathways [104] 
30 
 
   
 
Figure 8: Illustration showing epigenetic modifications which play a major role in 
regulating gene transcription. DNMT – DNA methyltransferase, MBD – Methyl 
binding domain, HAT – Histone acetyltransferase, H3K9 – Histone 3 at lysine 9, HDAC 





HYPOTHESIS AND SPECIFIC AIMS  
 
Key Objective 
To investigate effects of epigenetic modifications, such as DNA methylation, on 
aortic remodeling and hypertension during HHcy. 
Hypothesis  
Upregulation of global DNA methylation in hyperhomocysteinemia dysregulates cellular 
mechanisms causing endothelial dysfunction and adverse extracellular matrix remodeling 
leading to hypertension 
Specific Aims 
• Specific Aim 1: To determine whether HHcy increases the activity of 
methyltransferases and histone methylation to alter ECM metabolism in aorta. 
The experimental results associated with Aim 1 are presented in chapter IV. 
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• Specific Aim 2: To determine whether DNA methylation inhibitor, 5 Aza 2’ 
deoxycytidine (Aza) alleviates HHcy, improves smooth muscle and endothelial 
function and normalizes blood pressure. 
• Specific Aim 3: To determine whether Aza mediates its effects by modulating the 
expression of proteins involved in ECM regulation. 

























Figure 9: Schematic diagram of overall hypothesis. Epigenetic modifications regulate 


































AORTIC REMODELING IN HYPERHOMOCYSTEINEMIA  
Introduction 
Hcy is a risk factor for diseases such as stroke, ischemic heart disease, peripheral vascular 
and aortic diseases [105]. Although the normal range of homocysteine in the blood is 
around 5–15 µmol/L, the range varies with age and sex as well as nutritional factors 
[106]. HHcy is found in a study of 86 hypertensive patients compared to 82 normal 
healthy controls [107]. Plasma Hcy levels are positively correlated with blood pressure in 
human subjects with methionine loading [108]. Arteriosclerosis is prevalent in patients 
with increased homocysteine due to genetic defects in enzymes involved in Hcy 
metabolism, such as cystathionine beta-synthase (CBS) and methylene tetrahydrofolate 
(MTHFR) and in patients with nutritional deficiency of folic acid, vitamin B6 and B12.  
Hcy promotes arterial stiffness by increasing the synthesis of ECM components such as 
collagen. Collagen provides rigidity and structure to the arterial wall, while elastin 
provides distensibility by allowing blood vessels to resume their shape after stretch or 
contraction. During HHcy, the imbalance between elastin and collagen production 
destroys proper elasticity of the vessel and excessive collagen deposition causes vascular 
stiffness and tissue fibrosis. These effects increase vascular resistance for blood flow that 
results in arterial hypertension.  
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DNA methylation is an important epigenetic mechanism in transcriptional regulation of 
many genes. The methyl group is usually attached to the cytosine residue in the 
nucleotide sequence with the help of specific enzymes called DNA methyl transferases 
(DNMT) [109] There are two types of methylation involved – de novo methylation by 
DNMT 3a and DNMT 3b and maintenance methylation, by DNMT1.  Methyl binding 
domain (MBDs) proteins like MBD2 have been shown to bind to these methylated CpG 
islands and down-regulate transcription of downstream sequences by recruiting co-
repressor complexes [110]. These co-repressor complexes are proteins which are bound 
to chromatin remodeling proteins like Histone 3 which is trimethylated at lysine 9 
(H3K9) [111], and HDACs. Hcy induced DNA methylation plays an important role in 
atherosclerosis [112]. In the current study, aortic tissue samples from wild type mice 
(C57BL/6J) and CBS +/- mice ( with high methionine diet) were taken and mRNA 
expression levels of various genes involved in methylation such as DNMTs, MBD2 and 
H3K9 and genes involved in ECM metabolism such as collagen and elastin were 
measured to study the correlation of DNA methylation and ECM metabolism in HHcy. It 
was hypothesized that high levels of Hcy due to defects in methionine metabolism cause 




Mouse tissue samples 
CBS +/- (B6129P2) mice and their wild type littermates (WT, C57BL/6J) were obtained 
from The Jackson Laboratories. CBS +/- mice were fed with a high methionine diet for 
three weeks in order to create the HHcy condition. Aortic tissue was isolated from WT 
and CBS+/- mice. 
Blood Pressure Measurements 
Blood Pressure was measured by a noninvasive tail-cuff method (CODA; Kent Scientific, 
Torrington, CT). Animals were placed on a warming platform at 37C and allowed to 
acclimatize for 10 min before measurements were taken. Systolic, Diastolic and Mean 
arterial blood pressure were recorded in WT and CBS+/- mice.  
Plasma Hcy Measurement 
Plasma Hcy levels were measured using HPLC-UV as described before.[113-115] 
Reverse transcription polymerase chain reaction (PCR) 
Total RNA was isolated from mouse aortic tissue using Trizol reagent (Invitrogen) [116]. 
One microgram (1 µg) of total RNA was reverse transcribed using the Reverse 
Transcription System (Promega), according to the manufacturer’s instruction. Primers, to 
amplify specific gene sequences, were designed using Primer3 [117] and obtained from 
Invitrogen (Carlsbad, CA). The list of primers is given in Table 2. PCR was done in a 
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Biorad DNAEngine Thermal cycler (Hercules, CA). The PCR thermal cycle was 95C 
for 7 mins, 35 cycles of 95C for 50 s, 55C for 1min and 72C for 1min, and 72C for 5 
mins. PCR products were resolved by gel electrophoresis in 1% or 1.5 % agarose gels 
and the  images were recorded and analyzed using Imagelab software (Bio-Rad, 
Hercules, CA). The band intensities of the PCR product were normalized to GAPDH.  
Immunostaining 
Mouse aortic tissue was collected and cryo-blocks were prepared in Peel-A-Way 
disposable plastic tissue embedding molds (Polysciences Inc., Warrington, PA., USA) 
containing tissue freezing media (Triangle Biomedical Sciences, Durham, N.C., USA) 
and stored at -80°C until further use. Five micron (5 μm) tissue sections were made using 
a Cryocut (Leica CM 1850) and placed on Super frost plus microscope slides, air-dried 
and processed for immunohistochemistry (IHC). Slides were fixed using 3.7% 
paraformaldehyde, permeabilized and blocked with blocking solution (2% BSA and 0.5% 
Triton X-100 in PBS). Slides were incubated with mouse polyclonal anti-Histone 3 tri-
methyl K9 (Abcam, Cambridge, MA) overnight. Alexa Fluor 488 raised in mouse from 
Invitrogen (Carlsbad, CA) was used as the secondary antibody. The stained slides were 
mounted and visualized with a laser scanning confocal microscope (Olympus 
FluoView1000) with appropriate filters. Images were analyzed using Image Proplus 





Quantification of 5-methylcytosine 
Genomic DNA was extracted (Zymo Research Corp., Irvine, CA, USA) from the aortas 
of mice from the experimental groups. In order to measure levels of global methylation, 
the amount of 5-methylcytosine (5-mC) was determined using ELISA (Zymo Research 
Corp., Irvine, CA, USA), as per the manufacturer’s instructions. Samples were read at 
410 nm and the values are represented as percent of 5-mC 
Statistical Analysis 
Statistical analysis was done using Primer of Biostatistics to compare data collected from 
groups. Differences between CBS+/- and controls were determined by t-test. A 
probability level (p<0.05) is considered statistically significant. All values are presented 




Plasma Hcy and blood pressure measurements in CBS+/- mice 
Plasma Hcy levels in CBS+/- mice increased when compared to WT mice (Figure 10). 
Systolic, diastolic and mean blood pressure in CBS+/- mice was also increased when 
compared to WT mice (Figure 11).  
Expression of metabolites involved in remodeling proteins in mice aortic tissue 
samples 
To evaluate the expression of ECM fibrillar proteins, mRNA levels of collagen and 
elastin were assessed in WT and CBS+/- mice fed with a methionine diet (Figure 12).  On 
an average, the expression of Col1a1 in CBS+/- mouse aorta was increased when 
compared to WT but the increase did not reach statistical significance. The mRNA levels 
of Col4a1 were significantly increased in CBS +/- mouse samples when compared to WT 
controls.  In contrast, the level of Elastin was found to be decreased significantly in CBS 
+/- samples compared to WT (Figure 12).  
Expression levels of genes involved in epigenetic modifications in mouse aortic 
samples 
DNA methylation levels were analyzed by measuring %5-mC and mRNA levels of the 
enzymes, DNMT1, 3a and 3b that are involved in DNA methylation. CBS+/- mice had a 
higher %5-mC aortic content when compared to WT mice aorta suggesting global 
methylation in HHcy (Figure 13). There was an increasing trend of DNMT 1 and 3a 
levels in CBS +/- mice with high methionine diet when compared to WT mice (Figure 
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14). However, there was no change in DNMT3b levels in aortic samples from WT and 
CBS +/- mice. To study levels of methyl binding proteins and histone methylation, 
mRNA expression levels of MBD2 and H3K9 (trimethyl) respectively, were measured in 
CBS+/- mice. MBD2 and Histone 3 trimethylation in lysine 9 (H3K9) expression levels 
were increased in CBS +/- mice compared to WT (Figure 15, 16). However, there was no 
significant difference in the histone deacetylase 1 (HDAC1) mRNA levels between WT 









Figure 10: Plasma Hcy was increased in aortic tissue from CBS+/- mice. Plasma Hcy 
levels in WT and CBS+/- mice were measured using HPLC-UV. Data are shown as mean 






















Figure 11: Blood pressure was increased in HHcy mice. Blood pressure in WT and 
CBS+/- mice was measured by the tail-cuff method. Systolic, Diastolic and Mean blood 
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Gene Primer pair sequence (5’-3’) Product 
size (bp) 
Collagen - I AGAACTTTGCTTCCCAGATG 
CTATCTGTACCACCCCCTTG 
162 













































Figure 12: Collagen 4 was increased and elastin was decreased in HHcy. 
Representative RT-PCR image of collagen 1a1 (Col1A1), 4a1 and elastin mRNA 
expression. GAPDH was used as a loading control. The mRNA expressions were 
determined by densitometry analysis using Biorad Imagelab software. The intensity 
values were normalized by GAPDH intensity. n =3. Data are shown as mean ± SEM. *,# 
p<0.05 vs. WT.  


































Figure 13: Global hypermethylation in HHcy aorta. Bar graph representing percent 5-
mC detected in WT and CBS+/- mice aorta genomic DNA samples. Data are shown as 



































Figure 14: Increasing trend of DNMTs in aorta of HHcy mice. Representative RT-
PCR image of DNMT1, 3a and 3b mRNA expression. GAPDH was used as a loading 
control.  Graphical representation of mRNA expressions as determined by densitometry 
analysis using Biorad Imagelab software. Intensity values were normalized by GAPDH 
intensity. n =3. Data are shown as mean ± SEM.  















































Figure 15: Increasing trend in expression of methylation genes in aorta of HHcy 
mice.  Representative RT-PCR image of MBD2, H3K9 and HDAC1 mRNA expression. 
GAPDH was used as a loading control.  Graphical representation of mRNA expressions 
as determined by densitometry analysis using Biorad Imagelab software. The intensity 















































Figure 16: H3K9me3 expression was increased in HHcy mice aorta. Immunostaining 
of aorta sections with H3K9 (trimethyl) antibody (green fluorescence). Bar diagram 
indicate the intensity values as determined by Image Pro software. n =3. Data are shown 




























Previous studies report that Hcy is a leading risk factors which is responsible for 
aortic disease progression such as aortic dissection [5, 118, 119]. Elevated levels of Hcy 
in plasma, known as HHcy, trigger various effects such as impaired post-injury 
endothelial repair and function, deregulation of lipid metabolism, altered platelet activity, 
enhanced VSMC proliferation, activation of cellular immune response, all of which are 
believed to be primary characteristics in the development of vascular pathologies such as 
atherosclerosis and abdominal aortic aneurysm (AAA) [120-125]. Recent studies 
emphasize the role of epigenetic modifications such as DNA methylation in the 
regulation of the transcription of enzymes involved in various mechanisms including 
platelet activity and VSMC proliferation [126, 127]. The present study demonstrated the 
effect of HHcy on global DNA methylations in the aorta. Increased levels of plasma Hcy 
correlated with increased blood pressure in CBS+/- mice when compared to WT. 
Concurrent to our findings, Lim and Cassano et al., previously reported that a 5 μmol/L 
increase in plasma Hcy causes an increase of systolic and diastolic blood pressure by 
0.7/0.5 mmHg in men and 1.2/0.7 mmHg in women [108] 
 
Hcy increases the synthesis and accumulation of collagen in a dose dependent 
manner in VSMCs [124]. Atherosclerosis is characterized by increased smooth muscle 
proliferation and accumulation of ECM components, resulting in arterial intimal 
thickness [128-130]. Collagen provides rigidity to the artery wall and accounts for about 
60% of the ECM components responsible for the formation of atherosclerotic plaques 
[131]. Our results showed an increase in Collagen 1 and 4 levels in aortic tissue samples 
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from HHcy CBS +/- mice. In addition, a significant decrease in elastin levels in aortic 
tissue from CBS +/- mice was observed when compared to WT. An increased collagen to 
elastin ratio due to increased collagen and decreased elastin levels in CBS +/- mice 
accounts to carotid arterial remodeling [132]. Elastin provides distensibility to the vessel 
wall and a decrease in elastin content increases the vascular resistance to blood flow 
resulting in hypertension. These findings suggest that adverse aortic ECM remodeling 
associated with HHcy, may cause hypertension. 
HHcy alters the methylation patterns in the genome globally and in a gene 
specific manner. DNA methylation plays a predominant role in regulating gene 
expression. CBS knockout mice have a tissue specific fluctuation in their DNA 
methylation levels [133]. S- adenosyl methionine (SAM), an intermediate in the Hcy 
synthesis pathway, serves as the universal methyl donor for the methylation of various 
substrates such as DNA and proteins. Our results showed an increase in %5-mC and 
mRNA levels of DNMT1, and 3a in aortic tissue from HHcy mice. This finding 
suggested that an increase in synthesis of Hcy causes DNA hypermethylation. DNA 
methylation arrays in peripheral leukocytes of subjects with schizophrenia indicate a 
positive correlation between plasma Hcy and methylation of CpG residues in CpG islands 
[134]. Other epigenetic mechanisms such as histone methylation and methyl binding 
proteins act in conjunction to regulate genome wide transcriptional activity. The mRNA 
expression of MBD2 and Histone 3 trimethylated in Lysine 9 residue (H3K9) proteins 
suggested an increase in the expression of histone methylation and methyl binding 
proteins in HHcy. In addition, we studied mRNA expression of HDAC 1 but no 
significant change was found in the samples.  
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In summary, results of our study, combined with previous findings concerning the 
effect of Hcy on adverse ECM remodeling, delineate possible epigenetic mechanisms 
involved in aortic pathologies.  Although evidence suggests an association between gene 
promoter specific hyper-methylation and atherosclerosis [29], extensive studies of the 
role of methylation in regulating various genes up or down in other aortic pathologies 






EFFECT OF 5-AZA-2’DEOXYCYTIDINE IN AORTIC REMODELING IN 
HYPERHOMOCYSTEINEMIA 
Introduction 
Aortic disease is one of the most prevalent causes of increased mortality in the world 
[135-137]. Several risk factors including hyperglycemia, high serum cholesterol and 
elevated level of homocysteine (Hcy), known as hyperhomocysteinemia (HHcy), are 
associated with aortic aneurysm and atherosclerosis [138, 139]. The vascular pathology 
associated with HHcy is characterized by excess extracellular matrix (ECM) turnover, 
causing increased deposition of collagen, leading to vessel stiffness [140, 141]. Under 
physiological conditions, ECM homeostasis is maintained by equilibrium between matrix 
metalloproteinases (MMPs) and their inhibitors, tissue inhibitors of metalloproteinases 
(TIMPs). Previous literature demonstrated that HHcy increases the expression and 
activity of MMP-9 which causes matrix degradation and accumulation of collagen in the 
ECM [142]. Arterial hypertension is associated with endothelial dysfunction [143]. HHcy 
causes auto-oxidation of sulfhydryl groups, promoting reactive oxygen species 
production which uncouples endothelial nitric oxide synthesis and reduces nitric oxide 
(NO) synthesis and bioavailability [144-146]. A reduction in NO signaling further 
increases superoxide generation, forming a vicious cycle and impairs endothelial 
function. The functional consequence of endothelial dysfunction impairs vasodilation 
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resulting in arterial hypertension [147, 148]. Hcy is a non-protein coding amino acid 
synthesized by de-methylation of methionine. The methyl group which is excised during 
the synthesis of Hcy is used in various methylation reactions involving DNA, proteins, 
amino acids and Hcy [149].  DNA methylation is one of the most intensely studied 
epigenetic mechanisms in the development of aortic diseases. There are three DNA 
methyl transferases (DNMTs) involved in DNA methylation: DNMT1 which is involved 
in maintenance methylation and DNMT3a and 3b which catalyze de novo methylation 
[150]. Current research is focusing on the use of DNMT inhibitors in several disease 
conditions. Decitabine or 5-Aza-2’-deoxycytidine (Aza), a DNMT1 inhibitor is approved 
by the FDA for treatment of myelodysplastic syndrome (MDS). Other inhibitors such as 
Vidaza (5 Aza cytidine) are currently in phase 2 and phase 3 cancer trials [151]. 
The purpose of the present study was to investigate the role of DNA methylation in aortic 
ECM remodeling and vascular dysfunction in HHcy associated hypertension. We 
hypothesized that increased levels of Hcy and DNMT1 result in adverse ECM 
remodeling and endothelial dysfunction, leading to arterial hypertension. We also 
examined whether DNMT1 inhibitor, Aza could modulate ECM metabolism enzymes to 
mitigate hypertension. The results showed that Aza treatment in HHcy mice protects the 




Materials and Methods 
Antibodies and reagents 
Monoclonal antibodies to DNMT1, DNMT3b, Methylenetetrahydrofolate reductase 
(MTHFR) (mouse) and DNMT3a, MMP9, TIMP1, Hcy (rabbit) were purchased from 
Abcam (Cambridge, MA), mouse polyclonal antibody S-adenosyl homocysteine 
hydrolase (SAHH) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The 
following secondary fluorescent antibodies were used: Texas Red anti-rabbit, Alexa 
Fluor 488 anti-mouse from Invitrogen (Carlsbad, CA). The following horse radish 
peroxidase (HRP) conjugated secondary antibodies were used : anti-mouse and anti-
rabbit from Santa Cruz Biotechnology (Santa Cruz, CA). 
Animal Models 
Male C57BL/6J (wild type; WT) and Cystathionine beta-synthase heterozygous 
knockout; CBS +/- (B6129P2) mice, aged 8–12 weeks, obtained from Jackson 
Laboratories (Bar Harbor, ME) were used in this study. The disruption of the 
Cystathionine beta-synthase (CBS) gene in this heterozygous model, results in mild 
HHcy. All mice were fed standard chow (Lab diet 5010, St. Louis, MO) and water ad 
libitum. WT and CBS+/- mice were treated with 5-Aza-2’-deoxycytidine (Aza; Sigma, St. 
Louis, MO) for four weeks by intraperitoneal injection (100μL, 0.5mg/kg body weight; 
three consecutive times every week). Control animals received saline injections only. 
Animals were divided into four groups: WT, WT treated with Aza (WT+Aza), CBS+/-, 
and CBS+/- treated with Aza (CBS+/- +Aza). At least four animals (n ≥ 4) were used in 
each group. All procedures were done according to National Institutes of Health 
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guidelines and approved by the Institutional Animal Care and Use Committee of the 
University of Louisville, School of Medicine. 
Cell Culture 
Mouse aortic smooth muscle cells (SMCs) from ATCC (Manassas, VA) were cultured in 
6-well TPP (Techno Plastic Products, Trasadingen, Switzerland) cell culture plates with 
DMEM medium containing 10%FBS and 0.2 mg/ml G-418. Cells were allowed to grow 
to about 60% confluence and treated with 80µM Hcy and 100µM Aza for 48 hours.  
Blood Pressure Measurements 
Blood pressure (BP) was measured in conscious mice by a non-invasive tail cuff method 
(CODA, Kent Scientific, Torrington, CT). Animals were allowed to acclimatize in the 
restraining chambers on a warm platform for short duration (20-30 min) for a few days 
before data was recorded. Under standard conditions (room temperature, lighting, and 
quiet surroundings) BP was recorded weekly before and after starting Aza treatment 
including systolic, diastolic, and mean pressures. 
Ultrasound 
Under isoflurane anesthesia, aorta ultrasound was done using a Vevo 2100 system 
(Visual Sonics, Toronto, ON, Canada) before and after Aza treatment. The thoracic and 
abdominal area was depilated and the animal was placed supine on a warm platform 
(37°C). Using a MS550D (22-55 mHz) transducer, the thoracic and abdominal aorta were 
imaged. Cross-sectional images of the aorta in the B Mode were used to measure wall 
thickness and lumen diameter to obtain wall-to-lumen ratio. Peak systolic velocities 
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(PSV) and end-diastolic velocities (EDV) values were measured in pulsed-wave doppler 
mode. Resistive index (RI) was calculated using the following equation: RI = (PSV-
EDV)/PSV.  
Plasma Hcy metabolite levels 
Plasma levels of SAM, SAH and Hcy were analyzed using HPLC-UV as described 
before [113-115]. 
Vascular reactivity studies with aortic rings:  
Aortic ring preparation – The thoracic aorta was extracted from euthanized mice and 
immersed in Kreb’s solution (pH 7.4, 37 ° C) containing (in mM): 118 NaCl, 4.7 KCl, 
2.5 CaCl2, 1.2 KH2PO4, 1.2 MgSO4, 12.5 NaHCO3, and 10.9 D-glucose. Aortic rings 
were prepared by cutting 2 mm wide segments and attached to an isometric force 
transducer with two tungsten wire triangles [0.002 in. diameter, (Scientific Instruments 
Services, Ringoes, NJ)] in a tissue myobath (Radnoti, Monrovia, CA) which was 
continuously aerated with 95% O2-5% CO2. Rings were stretched to develop 0.5 g 
optimal resting tension and equilibrated for an hour to obtain baseline measurements 
using a DigiMed Tissue Force Analyzer (Micromed, Louisville, KY) [152].  
Response to Phenylephrine, Acetylcholine and Sodium Nitroprusside - After a baseline 
recording, vasoconstriction was studied by adding different concentrations of 
phenylephrine (Phe) from 10−6 to 10−2 M to the organ bath to make final concentrations 
of 10−9 to 10−5 M, respectively. Once maximal constriction was reached at 10-5M Phe, 
Acetylcholine (Ach) was added to the organ bath similar to Phe in gradually increasing 
concentrations to detect endothelial-dependent vasorelaxation. The tissue rings were 
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washed with fresh Kreb’s solution and pre-constricted with a maximum dose of Phe 
followed by 10-5M Sodium nitroprusside (SNP) to study endothelium-independent 
vasorelaxation. The tissue responses were recorded for 10 min for each drug 
concentration using DMSI-410 1.8.27 software (Micromed, Louisville, KY). 
Cryosectioning 
Aortic tissue was cryopreserved in Peel-A-Way disposable plastic tissue-embedding 
molds (Polysciences, Warrington, PA) containing tissue-freezing media (Triangle 
Biomedical Sciences, Durham, NC). Tissues were stored at –80°C until use. Serial 
sections of 7-μm thickness were made using a Cryocut (Leica CM 1850).  Cryosections 
were placed on Superfrost plus microscope slides, air dried and stored at –80°C until 
further use. 
Collagen staining 
To measure the deposition of collagen in the aortic wall, sections were stained with a 
Masson trichrome kit (Richard Allan Scientific, Kalamazoo, MI) following the 
manufacturer’s instructions. Collagen deposition is shown as blue color. Images were 
captured with a light microscope (Olympus FluoView1000; B&B Microscope Ltd, 
Pittsburg, PA). Sections were stained separately to differentiate type I and III collagen 
using Picrosirius red staining kit (Polysciences, Inc., Warrington, PA) [153]. Images were 






Immunofluorescence staining was done on 7-μm thick aortic sections using anti- 
MTHFR, MMP9, TIMP1, SAHH, DNMT1 and Hcy antibodies. Images were captured 
using a confocal microscope (Olympus FluoView1000; B&B Microscope Ltd, Pittsburg, 
PA) and analyzed by Image Proplus 7.0 software (Media Cybernetics, Inc., Rockville, 
MD).  
Immunoblotting 
Protein was extracted from cultured SMCs using RIPA lysis buffer (Boston BioProducts, 
Worcester, MA) with protease inhibitors. Protein concentration was determined using the 
Bradford assay and 50µg of total protein was loaded in SDS-PAGE gels. Protein was 
resolved by electrophoresis, transferred to a PVDF membrane and incubated with 
primary antibody and secondary HRP- conjugated antibody. Protein bands were detected 
using ECL substrate (Millipore, Billerica, MA). Bands were detected using Imagelab 
(Biorad, Hercules, CA) and normalized by a GAPDH control. The band intensities were 
quantified using ImageJ software.  
Gelatin Zymography 
Cultured SMCs were scraped with extraction buffer [10 mmol/l cacodylic acid, 20 ZnCl, 
1.5 NaN3 and 0.01% Triton X-100 (pH 5.0)] and incubated overnight at 4C with gentle 
agitation. The homogenate was centrifuged for 5 min at 10000 xg and the supernatant 
was collected. Protein concentration in the sample was measured using the Bradford 
method, and 100 µg of the protein was resolved in 10% SDS-PAGE containing 0.1% 
gelatin as MMP substrate. Gels were washed in renaturing buffer to remove SDS, rinsed 
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in water and incubated for at least 48 h in developing buffer at 37C in a water bath with 
gentle shaking. Gels were stained with 0.5% Coomassie brilliant blue for 1 h at room 
temperature. MMP activity in the gel was detected as white bands against a dark blue 
background. 
Quantification of 5-methylcytosine 
Genomic DNA was extracted from aorta and the amount of 5-methylcytosine (5-mC) was 
measured by ELISA following manufacturer’s instructions (Zymo Research Corp., 
Irvine, CA, USA). Values are presented as mean ± SEM as percent of 5-mC 
Statistical Analysis 
Statistical analysis was done using Primer of Biostatistics 7.0 (McGraw-Hill, New York, 
NY). One-way analysis of variance (ANOVA) followed by Bonferroni Correction was 
used for comparison between the experimental groups. Differences were considered 
















                        Figure 17: Schematic representation of the experimental plan 
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Effect of Aza on physiological parameters 
The body and heart weights of CBS+/- (HHcy) mice were lower than the WT groups 
(Figure 18). A significant increase was noticed following Aza treatment. The plasma Hcy 
level (Figure 19) was higher in CBS+/- mice when compared to WT groups. This can be 
explained from decreased SAM: SAH due to decreased levels of SAM and increased 
levels of SAH, precursors of Hcy in CBS+/- mice when compared to WT mice (Figure 
20). Following Aza treatment, SAM: SAH ratio was increased causing a decrease in 
plasma Hcy levels in CBS+/- mice. The baseline systolic, diastolic (Figure 21) and mean 
blood pressures (Figure 22) in CBS +/- mice were higher compared to WT groups. After 
4 weeks of Aza treatment, a significant decrease was observed in the BP of CBS+/- mice. 
Wall-to-lumen ratio and Resistivity Index 
HHcy causes aortic vessel remodeling. To analyze the structural changes in the aorta, we 
measured the lumen diameter and wall thickness of the ascending aorta and lumen 
diameter of abdominal aorta. The wall-to-lumen ratio of ascending aorta in CBS+/- mice 
was increased compared to WT groups (Figure 23). Similarly, the diameter of abdominal 
aorta in CBS+/- mice was significantly decreased from WT and WT + Aza mice (Figure 
25). After Aza treatment, the wall-to-lumen ratio of the ascending aorta decreased and the 
lumen diameter of abdominal aorta increased in CBS+/- mice and was similar to WT 
groups. Resistive index (RI) is a measure of the resistance of the vessel to blood flow.  
The RI of ascending (Figure 24) and abdominal aortas (Figure 26) were increased in 
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CBS+/- mice compared to WT groups and significantly decreased following Aza 
treatment.   
Aortic response to Phenylephrine, Acetylcholine and Sodium Nitroprusside 
To evaluate effect of Aza on aortic function, the response of aortic rings from the 
experimental groups to vasoconstriction and vasorelaxation in response to Phe and Ach 
respectively, was tested in a dose-dependent manner. Aortas from CBS+/- mice were 
nearly three-fold  and seven-fold less responsive to Phe (Figure 27) and Ach (Figure 28) 
compared to WT groups. Similarly, endothelium-independent relaxation to maximum 
concentration of SNP was reduced by three-fold (Figure 29) in CBS+/- mice compared to 
WT groups. Aza treatment restored the aortic responses to Phe, Ach and SNP so that they 
were similar to WT groups.  
Effect of Aza on collagen deposition 
Collagen deposition was quantified in the aorta as an indication of vascular stiffness. WT 
groups without or with Aza showed normal blue intensity, whereas, increased intensity 
was observed in CBS+/- mice suggesting increased collagen deposition in the adventitia 
(Figure 30). Aza treatment reduced total collagen content by 2.4-fold compared to its 
untreated control. Under polarized light filter, picrosirius red stain shows type I collagen 
as yellow and type III as a green color (Figure 31). Type I and III collagen from WT 
without Aza treatment was considered normal and used for further analysis. Aorta from 
WT+Aza did not differ from its control (Figure 31). In contrast, CBS+/- mice showed 
3.8-fold increase in type I and a 4.5-fold increase in type III collagen compared to 
untreated WT mice (Figure 31). Following treatment with Aza in CBS+/- mice type I 
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collagen decreased by two-fold and type III by 1.5-fold compared to untreated CBS+/- 
mice (Figure 31).  
DNMT1 inhibition decreases expression of ECM remodeling and Hcy synthesis and 
triggers Hcy remethylation 
To examine effects of Aza treatment on the expression of proteins involved in Hcy 
metabolism, we measured the expression of MTHFR, SAHH and Hcy by 
immunostaining. There was an eight-fold increase in Hcy and two-fold increase in SAHH 
expression (Figure 32) in CBS+/- mice compared to WT groups. MTHFR expression was 
decreased by 1.5-fold in CBS+/- mice (Figure 32) compared to WT groups. These results 
suggested an up-regulation of Hcy synthesis and down-regulation of Hcy remethylation 
pathway in CBS+/- mice. Aza treatment decreased the expression of Hcy and SAHH and 
increased MTHFR in CBS+/- mice which were similar to WT controls. To evaluate the 
expression of ECM remodeling genes, we measured the expression of MMP9 and TIMP1 
(Figure 33). There was a three-fold increase in MMP9 and 2.6-fold increase in TIMP1 in 
CBS+/- mice (Figure 33) compared to WT control. Following Aza treatment their levels 
were reduced and were similar to WT groups. MMP9 activity in cultured SMCs was 
quantified using gelatin zymography. Hcy treatment increased MMP9 activity in SMCs 
and following Aza treatment, MMP9 activity was decreased following Aza treatment 
(Figure 34).  
Global DNA Methylation in hyperhomocysteinemia 
To better understand the effect of HHcy on maintenance methylation, we measured the 
expression of DNMT1 in all the groups. There was a three-fold increase in DNMT1 
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expression in CBS+/- mice compared to WT controls, which was normalized by Aza 
treatment (Figure 35). Similarly there was an increase in DNMT1 and 3b expression in 
Hcy treated SMCs which was reduced after treatment with Aza (Figure 36). To determine 
the overall methylation levels in aorta during HHcy, we measured 5-methylcytosine (5-
mC) from the extracted DNA. As shown in Figure 37, we observed a significant increase 
in methylation levels in CBS+/- mice compared to WT groups. Following treatment with 
Aza there was a significant reduction in the CBS+/- mice compared to its control. There 
was an increase in global methylation levels in Hcy treated SMCs. Following Aza 







    
            
 
 
 Figure 18: Effect of Aza treatment on gravimetric parameters. Bar graph 
representing gravimetric data i.e. body and heart weight. Data are shown as mean±SEM.  















































Figure 19: Aza treatment normalized plasma Hcy levels. Bar graph representing 
plasma Hcy level in all groups was measured using HPLC-UV. Data are shown as 


























Figure 20: Aza treatment normalized SAM/SAH ratio. Bar graphs represent plasma 
SAM and SAH levels in all experimental mice were measured using HPLC-UV. Data are 






































































Figure 21: Aza treatment normalized systolic and diastolic blood pressure in HHcy 
mice. Blood Pressure was measured using tail cuff method. Line graphs represent the 
systolic and diastolic blood pressure. Values are expressed as mean ± SEM. n=4; * p < 
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Figure 22: Aza treatment normalized mean blood pressure in HHcy. Blood Pressure 
was measured using tail cuff method. Line graphs represent the mean blood pressure. 
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Figure 23: Aza treatment normalized ascending aorta wall-to-lumen ratio in HHcy. 
B-mode ultrasound image of ascending aorta. Wall thickness (mm) and lumen diameter 
(mm) were measured by Vevo 2100 (Visual Sonics Vevo Ultra Imaging System). Bar 
graphs of wall-to-lumen ratio of ascending aorta represented as mean ± SEM. n=4, * p < 
0.05 vs. WT and WT+Aza; † p < 0.05 vs. CBS 
WT 
CBS +/- 











































Figure 24: Aza treatment normalized ascending aorta resistive index. Pulse Wave 
mode images of ascending aorta. Resistive index (RI) estimated the resistance offered by 
the aorta and is calculated as (PSV-EDV)/EDV. RI was measured by Vevo 2100 (Visual 
Sonics Vevo Ultra Imaging System) Bar graphs represent mean RI ± SEM in ascending 
aorta. n=4, * p < 0.05 vs. WT and WT+Aza; † p < 0.05 vs. CBS  
WT 
CBS +/- 









































Figure 25: Aza treatment normalized abdominal aorta lumen diameter. B-mode 
ultrasound image of abdominal aorta. Lumen diameter (mm) was measured by Vevo 
2100 (Visual Sonics Vevo Ultra Imaging System). Bar graphs represent the lumen 
diameter of abdominal aorta represented as mean ± SEM. n=4, * p < 0.05 vs. WT and 
WT+Aza; † p < 0.05 vs. CBS 
WT 
CBS +/- 












































Figure 26: Aza treatment normalized abdominal aorta resistive index. Pulse Wave 
mode images of abdominal aorta. Resistivity Index (RI) was measured by Vevo 2100 
(Visual Sonics Vevo Ultra Imaging System). Bar graphs represent mean RI ± SEM in 
ascending aorta. n=4, * p < 0.05 vs. WT and WT+Aza; † p < 0.05 vs. CBS  
WT 
CBS +/- 




































Figure 27: Aza treatment improved aortic response to Phe. Aorta was extracted from 
experimental mice (WT, WT+Aza, CBS, CBS+Aza) following protocol described in 
Materials and Methods. Aortic rings were mounted in myobath containing Kreb’s 
solution. The rings were treated with phenylephrine (Phe) in a dose dependent manner as 
described in Materials and Methods. Data are shown as n=4; * p < 0.05 vs. WT and 
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Figure 28: Aza treatment improved aortic response to Ach. Aorta was extracted from 
experimental mice (WT, WT+Aza, CBS, CBS+Aza) following protocol described in 
Materials and Methods. Aortic rings were mounted in myobath containing Kreb’s 
solution. Rings were treated with acetylcholine (Ach) in a dose dependent manner as 
described in Materials and Methods. Data are shown as n=4; * p < 0.05 vs. WT and 









































Figure 29: Aza treatment improved aortic response to SNP. Aorta was extracted from 
experimental mice (WT, WT+Aza, CBS, CBS+Aza) following protocol described in 
Materials and Methods. Aortic rings were mounted in myobath containing Kreb’s 
solution. Rings were treated with sodium nitroprusside (SNP) in a dose dependent 
manner as described in Materials and Methods. Data are shown as n=4; * p < 0.05 vs. 









































Figure 30: Collagen expression was decreased post Aza treatment. Collagen is 
stained as dark blue. Original image, x 20 magnification. Bar graph represents the % 
mean intensity ± SEM of blue color in the aorta. n=4, * p < 0.05 vs. WT and WT+Aza; † 
p < 0.05 vs. CBS   
WT 
CBS+/- 








































Figure 31 A: Aza treatment decreased collagen I and III in HHcy. Picrosirius red 
staining for type I and type III collagen (yellow and green colors represent type I and type 
























Figure 31 B: Aza treatment decreased collagen I and III in HHcy. Bar graph 
represents % mean intensity ± SEM of yellow (Type I) and green (Type III) color in 





































































Figure 32A: Aza treatment decreases Hcy accumulation. The protein expressions of 
SAHH, Hcy and MTHFR were measured. Expression of MTHFR and SAHH are shown 
as green fluorescence and expression of Hcy is seen as red fluorescence. Original image, 
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Figure 32B: Aza treatment decreases Hcy accumulation. Bar graph representations of 
the IHC images. Y-axis represents % change mean intensity ± SEM. n=4; * p < 0.05 vs. 
















































Figure 33A: Aza treatment normalizes the expression of MMP9 and TIMP1 in 
HHcy. The protein expressions of MMP9, TIMP1 were measured. Expression of MMP9 













Figure 33B: Aza treatment normalizes the expression of MMP9 and TIMP1 in 
HHcy. Bar graph representations of the IHC images. Y-axis represents % change mean 
intensity ± SEM. n=4; * p < 0.05 vs. WT, WT+Aza and CBS+Aza; † p < 0.05 vs. WT, 








































Figure 34: Aza treatment decreased MMP9 activity in Hcy treated SMCs. Gelatin 
zymography was done to analyze the activity of MMP9 in Aza and Hcy treated SMCs. 























































Figure 35: Aza treatment decreases DNMT1 in HHcy. The protein expressions of 
DNMT1 were measured. Expression of DNMT1 is shown as green fluorescence. Bar 
graph representations of the IHC images. Y-axis represents % change mean intensity ± 












































Figure 36: Aza treatment decreases DNMT1, 3b in Hcy treated SMCs. 
Immunoblotting of DNMT1, 3a and 3b. Bar graphs show the relative expression of 
DNMT1, 3a and 3b over controls, after normalization with GAPDH. The data are shown 







































Figure 37: Aza treatment decreases global methylation levels in aorta. Overall 
methylation levels were measured using ELISA. The bar graphs represent the mean %5-



























Figure 38: Aza treatment decreases global methylation in SMCs. Overall methylation 
levels were measured using ELISA. The bar graphs represent the mean %5-mC ± SEM; 






















HHcy plays a critical role in the development of various aortic diseases [154-157]. HHcy 
induces the expression of MMPs involved in ECM metabolism, promoting aortic 
remodeling resulting in arterial hypertension [141]. Epigenetic mechanisms such as DNA 
methylation are known to control the expression of ECM components [158]. Although 
various studies report aberrant DNA methylation pattern in early stages of atherosclerosis 
[159] and aortic aneurysm [29], the role of DNA hypermethylation on aortic remodeling 
and arterial hypertension in HHcy still remains unclear. In the recent years, epigenetic 
inhibitors are being used as therapeutic agents in various cancer drug trials [151] . Our 
study provides new insights into the mechanism and the use of epigenetic inhibitors as 
therapeutic option in hypertension associated aortic pathologies.   
In the present study, we used CBS+/- mice as HHcy model. In a previous report, Gupta et 
al., demonstrate that CBS deficient mice have decreased fat mass due to reduction in 
lipogenesis [160]. Our observation of reduced body weight in CBS+/- mice supported 
this earlier finding. Plasma Hcy level is an important predictor of pulse pressure in 
hypertensive subjects [161]. In the previous study, increased plasma Hcy in CBS+/- mice 
was associated with elevated systolic, diastolic and mean blood pressure. Evidence from 
earlier studies suggest that lowering plasma Hcy level by supplemental vitamins such as 
folic acid, B6 and B12 is effective in delaying the formation of atherosclerotic plaques 
[162]. Our results showed that Aza lowers plasma Hcy in CBS+/- mice to normal levels. 
Plasma levels of S-adenosyl homocysteine (SAH), precursor of Hcy, is correlated to Hcy 
levels [125]. S-adenosyl methionine (SAM) and SAH levels were decreased and 
increased respectively in HHcy mice. Aza treatment reversed this effect in CBS+/- mice. 
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During HHcy, the conversion of SAM to SAH liberates excess methyl groups which are 
used in methylating substrates including DNA and proteins. Indeed hypermethylation of 
gene promoters occurred in hypertension. For example, sulfatase 1, (SULF1) gene, an 
endosulfatase, has been reported to be hypermethylated in hypertensive subjects [163]. In 
our study, we showed that Aza treatment in hypertensive CBS+/- mice restored systolic, 
diastolic and mean blood pressure to normal levels, which suggested an important role for 
hypermethylation in HHcy associated hypertension.  
Excessive accumulation of ECM proteins in HHcy causes hypertrophic vascular 
remodeling by increasing the wall thickness and decreasing lumen diameter. [62, 164]. In 
the present study, ultrasound examination revealed increased wall-to-lumen ratio of 
ascending aorta and decreased lumen diameter of abdominal aorta in CBS+/- mice. In an 
earlier study from our lab, treatment of CBS+/- mice with SAH hydrolase inhibitor,  
(Deazaadenosine, DZA), decreased systolic blood pressure without a change in the aortic 
wall-to-lumen ratio within the first week of treatment [141]. This result suggested that the 
reduction in systolic blood pressure was secondary to reduction in cardiac output 
preceding structural remodeling [141]. In the present study, we show that Aza treatment 
decreased BP at three weeks suggesting a significant role for epigenetic mechanism in 
aortic remodeling during HHcy-induced hypertension. The reduction in blood pressure 
(systolic, diastolic and mean) was associated with a reduction in wall-to-lumen ratio of 
ascending aorta and increase in lumen diameter of abdominal aorta.  Resistive index (RI) 
of aorta was measured as an indication of resistance to blood flow. In previous literature, 
a positive correlation was reported for carotid artery RI and atherosclerosis [165]. In our 
study, increased RI in CBS+/- suggested vascular stiffness and was associated with 
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increased MMP9 activity and TIMP1 expression. The increase in TIMP1 appears to be 
compensatory to increased MMP9. Consistent with our findings, increased MMP9 and 
TIMP1 occurs in pathologies such as neonatal encephalopathy [166] and aortic aneurysm 
[167]. Our results demonstrated that Aza treatment reduces collagen deposition and also 
decreases MMP9 and TIMP1 expression in HHcy. The reduction in the wall-to-lumen 
ratio and RI upon Aza treatment suggested mitigation of aortic ECM remodeling. 
Although previous studies reported no significant changes in smooth muscle contraction 
(Phe) [168] or endothelium-independent relaxation (SNP) [169] between WT and HHcy 
mice, we saw a significant decrease in the aortic response to Phe, Ach and SNP in HHcy 
mice. Consistent with our findings, Tyagi et al [170]  reported that HHcy mice showed 
decreased response to vasoconstrictor (Endothelin-1) compared to controls. In the present 
study, the impairment of vessel function suggests endothelial and smooth muscle 
dysfunction and vascular stiffness. Aza treatment improved vascular response to Phe, 
Ach and SNP in HHcy and also reduced vessel stiffness as indicated by reduction of 
collagen deposition. This suggested that DNMT1 inhibition improved aortic function 
during HHcy thereby mitigates hypertension. 
Hcy is derived from de-methylation of dietary methionine. S-adenosyl homocysteine 
hydrolase (SAHH) plays a major role in the synthesis of Hcy from S-adenosyl 
homocysteine. Following synthesis, Hcy has two fates: a) transsulfuration to cysteine 
aided by CBS and b) remethylation to methionine by MTHFR in the folate metabolism 
pathway [149]. Previous study shows that in HHcy, betaine Hcy methyltransferase 
(BHMT) and formation of 5-methyltetrahydrofolate by methylenetetrahydrofolate 
reductase (MTHFR) is inhibited [171]. The fate of homocysteine in the body is controlled 
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by a balance between the remethylation and transsulfuration pathways. During high 
methionine diet, Hcy catabolism is increased favoring transsulfuration over 
remethylation. In contrast, with a low methionine diet the remethylation pathway was 
favored compared to transsulfuration [149]. Since CBS is a key enzyme in Hcy 
metabolism, genetic mutations in CBS [172] and dietary deficiency of amino acids such 
as methionine or taurine and vitamins (folate and B12) can affect the plasma Hcy 
concentrations. In a recent study, Tang et al demonstrated that when WT and transgenic 
mice expressing human CBS were fed a low methionine diet, the protein levels of CBS in 
the liver and the activity were decreased to conserve methionine levels in the body [173]. 
In the transsulfuration pathway, Hcy is catabolized to yield taurine which reduces total 
serum cholesterol by lowering very low density lipoprotein (VLDL) and low density 
lipoprotein (LDL) [174]. When CBS+/- mice were fed taurine deficient diet, there was an 
upregulation of CBS monoallele along with a reduction in total serum cholesterol levels. 
These studies suggest the impact of enzymes involved in Hcy metabolism such as CBS, 
SAHH and MTHFR in maintaining plasma Hcy levels. In the present study, 
immunostaining analysis revealed an upregulation of SAHH and Hcy expression and 
downregulation of MTHFR in the aorta from HHcy mice. Also, a previous study suggests 
a negative correlation between the concentration of SAH and MTHFR expression [125]. 
Upon treatment with Aza, there was a reduction in the SAHH expression and increase in 
MTHFR suggesting increased remethylation to reduce plasma Hcy levels. 
Previous reports in the literature link HHcy to both global hypermethylation [175] and 
hypomethylation [176]. A study by Zhang et al., showed that the effect of Hcy on 
methylation patterns of gene promoters was dependent on Hcy concentration. HHcy is 
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known to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH2), an 
enzyme involved in the nitric oxide synthase pathway, causing endothelial dysfunction. 
Previous studies report hypermethylation of DDAH2 promoters in HHcy [177]. Also, an 
earlier study in our lab, showed increased DNMT1 expression in HHcy mice suggesting 
hypermethylation [37]. In the present study, we confirmed global hypermethylation by 
quantitating %5-mC in HHcy mice aorta and Hcy treated SMCs. Treatment with Aza 
decreased the expression of DNMT1, 3b and also reduced global methylation levels. 
Although previous results suggest a positive correlation between SAM/SAH ratio and 
DNA methylation [178], we found DNA hypermethylation with decreased SAM/SAH 
ratio in Hcy mice. The decrease in SAM/SAH ratio suggests an increased Hcy production 
accompanied by an increased availability of methyl groups for DNA methylation.   
An approach to alleviate HHcy mediated aortic pathology is to lower plasma Hcy levels. 
Although folic acid supplementation decreases Hcy level to prevent disease progression, 
it is unable to reverse the existing HHcy induced aortic pathology, termed as Hcy 
memory effect [178]. The present study for the first time provides evidence that 
epigenetic DNMT inhibitor can be a potential therapeutic agent independently or in 
combination with other therapies such as folic acid in aortic diseases. 
In conclusion, HHcy promotes pathological aortic remodeling and endothelial 
dysfunction leading to arterial hypertension. Inhibition of DNMT1, using Aza, 
ameliorates Hcy level and reduces high blood pressure. Aza appears to mediate its action 
by modifying the expression of enzymes involved in Hcy metabolism and ECM proteins 




SUMMARY, CONCLUSION AND FUTURE DIRECTIONS 
Cardiovascular diseases are the leading cause of death worldwide. HHcy is 
identified as one of the primary risk factors for cardiovascular diseases such as diseases 
of the aorta [5, 139]. An elevation of the plasma Hcy level correlates with blood pressure 
in human subjects with methionine loading [108]. Arterial stiffness and vascular 
dysfunction are the characteristic features that contribute to cardiovascular diseases such 
as atherosclerosis, which causes resistance to blood flow leading to hypertension [20]. 
Previous studies suggest an increased accumulation of ECM components such as 
collagen and MMPs in cardiovascular diseases causing ECM remodeling [61]. Epigenetic 
modifications such as DNA methylation and histone modifications regulate the 
expression of cellular proteins. Furthermore, evidence suggests a role of DNA 
methylation in HHcy associated pathologies. Therefore, epigenetic inhibitor therapies are 
currently being considered as a promising approach in various diseases. 
In the first set of experiments it was found that in CBS+/- mice, increased levels 
of plasma Hcy caused an increase in the synthesis and accumulation of ECM 
components. Increased collagen deposition and decreased elastin levels contributed to 
aortic stiffness providing resistance to the incoming blood flow. This narrowing of blood 
vessels contributes to the development of arterial hypertension. Epigenetic mechanisms 
played a major role in regulating the transcription of these ECM remodeling genes.  
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HHcy triggers epigenetic changes by increasing the expression of enzymes involved in 
epigenetic modifications such as DNA methylation (DNMT1, 3a, MBD2) and Histone 
methylation (H3K9). These changes contributed to increased genome-wide global DNA 
methylation levels thereby regulating various pathways. 
In the second set of studies, to ascertain the effect of DNA methylation in aortic 
remodeling in HHcy, CBS+/- mice were treated with an epigenetic inhibitor, Aza.   Aza 
treatment decreased global hypermethylation by inhibiting DNMT1 and hence lowered 
plasma Hcy levels in CBS+/- mice. Aza treatment also decreased ECM remodeling by 
lowering the expression of MMP9 and deposition of collagen in the aorta wall causing 
decreased wall to lumen ratio and resistive index thus mitigating hypertension in HHcy 
mice. Hence, treatment with epigenetic inhibitors is a possible therapeutic approach to 
prevent HHcy associated pathological remodeling. 
Future Directions:   
Hypertension-induced aortic remodeling is a complex process involving enzymes that 
synthesize ECM components and their regulators such as MMPs and TIMPs. This study 
mainly focused on the effect of an epigenetic inhibitor, Aza, on ECM remodeling 
proteins (MMP9, TIMP1, Collagen) and Hcy metabolism enzymes (SAHH, MTHFR) in 
the aorta. However, as the enzymes involved in Hcy metabolism are located in other 
organs such as kidney and liver, additional studies are required to quantitate the specific 
effect of Aza on individual enzymes involved in Hcy metabolism. Although this study 
provides evidence of impairment in vascular function in HHcy mice and its improvement 
with Aza, understanding the mechanism by which HHcy affects promoter methylation of 
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